Protara Therapeutics, Inc.
TARA
$5.42
$0.163.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.73% | 21.34% | 36.08% | 21.28% | 3.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.31% | 19.71% | 55.58% | 19.18% | 29.63% |
| Operating Income | -33.31% | -19.71% | -55.58% | -19.18% | -29.63% |
| Income Before Tax | -35.54% | -18.17% | -57.26% | -7.38% | -24.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.54% | -18.17% | -57.26% | -7.38% | -24.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.54% | -18.17% | -57.26% | -7.38% | -24.93% |
| EBIT | -33.31% | -19.71% | -55.58% | -19.18% | -29.63% |
| EBITDA | -33.42% | -19.81% | -55.87% | -19.32% | -30.14% |
| EPS Basic | 22.19% | 37.58% | 21.00% | 69.87% | 46.28% |
| Normalized Basic EPS | 22.19% | 37.58% | 21.00% | 69.88% | 46.29% |
| EPS Diluted | 22.19% | 37.58% | 21.00% | 69.87% | 46.28% |
| Normalized Diluted EPS | 22.19% | 37.58% | 21.00% | 69.88% | 46.29% |
| Average Basic Shares Outstanding | 74.18% | 89.31% | 99.08% | 256.43% | 132.58% |
| Average Diluted Shares Outstanding | 74.18% | 89.31% | 99.08% | 256.43% | 132.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |